Virulence: Likely Increased.
Antigenicity: C.37 variant is possibly resistant to therapeutic monoclonal antibodies, natural infection’s or vaccine-induced antibodies.
Spread: Originally was discovered in Peru and has now spread to 29 countries. Variant is dominant in Peru, Chile, Mexico, Equador, but prevalence also growing fast in US, as well as some European countries.
Global Positive Samples Sequenced: 5,628,45
C.37 Sequenced: 8,659
% of Global Samples Sequenced: 0.15%
Most common countries: Peru 44.0%, Chile 20.0%, United States of America 13.0%, Argentina 11.0%, Ecuador 3.0% (Alias of B.22.214.171.124, lineage in Peru, Chile, USA and Germany, from pango-designation issue #52).
Global Samples Sequencing Data
Updated December 2021